BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer
In this cohort, using a careful methodology, BRCA1/2 and PALB2 mutation carriers had reduced PFS with first-line ET + CDK4/6i compared to wild-type patients.
Authors
- Amélie Lusque (ORCID: https://orcid.org/0000-0001-9691-5536)
- Caroline Bailleux (ORCID: https://orcid.org/0000-0003-4188-3367)
- Timothé Guinel
- Vincent Massard
- Severine Guiu
- Lise Bosquet
- Thomas Bachelot
- Suzette Delaloge
- William Jacot
- Isabelle Desmoulins
- Monica Arnedos
- Audrey Mailliez
- Christelle Levy
- Thibault de la Motte Rouge
- Etienne Brain
- Anthony Goncalves
- Jean-Sébastien Frénel
Institutions
- Institut Gustave Roussy (FR)
- Centre Georges François Leclerc (FR)
- Institut de Cancérologie de Lorraine (FR)
- Centre François Baclesse (LU)
- Centre Léon Bérard (FR)
- Institut de Cancérologie de l'Ouest (FR)
- Centre Eugène Marquis (FR)
- Centre François Baclesse (FR)
- Institut Claudius Regaud (FR)
- Centre Oscar Lambret (FR)
- Institut Bergonié (FR)
- Institut de Recherche en Cancérologie de Montpellier (FR)
- UniCancer Group (FR)
- Institut Paoli-Calmettes (FR)
- Centre Antoine Lacassagne (FR)
- Institut Curie (FR)
Publication Details
- Journal
- The Breast
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1016/j.breast.2026.104739
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Les Laboratories Pierre Fabre
- Clovis Oncology
- Institut de Cancérologie de Lorraine
- Unicancer
- Genentech
- Fox Chase Cancer Center
- Daiichi Sankyo Europe